Previous 10 | Next 10 |
BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, today announced that management will participate in a fireside chat at ...
X4 Pharmaceuticals, Inc. (XFOR) Q3 2022 Results Conference Call November 03, 2022 08:30 AM ET Company Participants Dan Ferry - LifeSci Advisors Paula Ragan - Chief Executive Officer Diego Cadavid - Chief Medical Officer Mark Baldry - Chief Commercial Officer ...
X4 Pharmaceuticals press release ( NASDAQ: XFOR ): Q3 GAAP EPS of -$0.26 beats by $0.04 . X4 had $81.1 million in cash, cash equivalents, and restricted cash as of September 30, 2022. X4 believes that it has sufficient funds to support company operations into the third...
Following positive mavorixafor Phase 1b data release in multiple chronic neutropenic disorders, X4 continues to look forward to top-line results from its pivotal Phase 3 trial in WHIM syndrome in the fourth quarter of 2022 Conference call to be hosted today at 8:30 a.m. ET...
A seasoned leader in the launch of rare and specialty pharmaceuticals, Mr. Baldry is expected to join X4 on November 3, 2022 BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small-mole...
BOSTON, Oct. 20, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the immune system, today announced that it will be reporting financial results for t...
X4 Pharmaceuticals ( NASDAQ: XFOR ) said its drug mavorixafor helped in increasing a type of white blood cell called neutrophil in people with chronic neutropenia (CN) in a phase 1b trial. Neutropenia occurs when the body has too few neutrophils. The study ...
100% of study participants (n=25) achieved robust responses to oral mavorixafor 100% of neutropenic participants (n=14) achieved normalized neutrophil counts Robust responses achieved across all CN disorders studied (idiopathic, cyclic, congenital); estimated diagnos...
Summary X4 Pharmaceuticals is advancing Mavorixafor, a once-daily oral dose, first in class, small molecule antagonist of the CXCR4 receptor in WHIM syndrome and in chronic neutropenia disorders. On Sept 27, topline results will be presented from a Phase 1b trial testing Mavorixaf...
BOSTON, Aug. 31, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small-molecule therapeutics to benefit people with diseases of the immune system, today announced that it will host an investor webina...
News, Short Squeeze, Breakout and More Instantly...
X4 Pharmaceuticals Inc. Company Name:
XFOR Stock Symbol:
NYSE Market:
X4 Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 30.9% to $0.6 on volume of 558,931,853 shares NVIDIA Corporation (NVDA) fell 1.9% to $123.99 on volume of 249,243,816 shares Assure Holdings Corp. (IONM) rose 82.8% to $0.424 on vol...
100% of evaluable participants at Month 6 achieved target absolute neutrophil count (ANC) increase with once-daily, oral mavorixafor +/- stable-dose G-CSF as of the interim analysis data cut-off date Durable mean ANC levels above the lower limit of normal for CN were achieved for partic...
BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will host a virtual investor event on Thursday, June 27, 2024 at 8:00 am ET. To register for the eve...